The Future of Cancer Diagnostics Webinar with Q&A – April 2025

We hosted a virtual investor event, showcasing the data and strategic updates on our Nu.Q^® platform for cancer detection and monitoring.

Led by Chief Commercial Officer Gael Forterre, Chief Medical Officer Dr. Andrew Retter, and Chief Scientific Officer Dr. Jake Micallef, the event highlighted the completion of several large independent studies that further validated the clinical utility of Nu.Q^® assays.

Key takeaways included:

• A detailed look at Volition’s commercialization progress, including developments in both licensing and sales channels.

• Insight into the role of Nu.Q^® in lung cancer care, from early screening through to monitoring treatment response and disease progression—addressing a potential $4 billion market.

• Presentation of data (currently under peer review) showing that Nu.Q^® can detect multiple common cancers—including lung, breast, prostate, colon, and liver—with an overall AUC of 86% and very low false positive rates, underscoring its potential to disrupt the $20 billion U.S. liquid biopsy market for multi-cancer early detection.

The event concluded with an interactive Q&A session, reflecting strong interest from the investor community in Volition’s mission and momentum.

Volition continues to lead in the field of epigenetics, developing accessible and cost-effective blood-based diagnostics with the potential to transform early detection and disease monitoring worldwide.

Be the first to hear about Volition’s latest breakthroughs, clinical milestones, and investor updates: sign up for our email newsletter.